Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind Expanded Genetic Alphabet platform technology expands the genetic code by adding a new DNA base pair and is designed to create optimized biologics, referred to as Synthorins. A Synthorin is a protein optimized through incorporation of novel amino acids encoded by the new DNA base pair that enables site-specific modifications, which enhance the pharmacological properties of these therapeutics. The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries in Dr. Floyd Romesberg’s lab at The Scripps Research Institute. Synthorx is headquartered in La Jolla, California.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 11099 North Torrey Pines Road, Suite 290, La Jolla,ca 92037,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- synthorx.com
- HQ
- La Jolla, CA
Synthorx Inc Questions
Synthorx Inc's website is synthorx.com
Synthorx Inc's LinkedIn profile is https://www.linkedin.com/company/synthorx-inc-
Synthorx Inc has
5 employees.
View email and phone details for 5
employees at Synthorx Inc.
Synthorx Inc's industry is
Biotechnology Research
Synthorx Inc's top competitors are
Tentarix Biotherapeutics,
Coi Pharmaceuticals,
Ars Pharmaceuticals, Inc.,
Capstan Therapeutics,
Anaptysbio,
Abzena,
Tektonyx Bio, Inc.,
Janux Therapeutics,
Telesis Bio,
Enlaza Therapeutics.
Synthorx Inc's categories are Biotechnology Research
Synthorx Inc's founding year is 2014
